GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Market Cap

Adynxx (Adynxx) Market Cap : $0.00 Mil (As of Apr. 27, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Adynxx's share price for the quarter that ended in Sep. 2019 was $1.5. Adynxx's Shares Outstanding (EOP) for the quarter that ended in Sep. 2019 was 5.81 Mil. Therefore, Adynxx's market cap for the quarter that ended in Sep. 2019 was $8.71 Mil.

Adynxx's quarterly market cap increased from Mar. 2019 ($14.72 Mil) to Jun. 2019 ($16.90 Mil) but then declined from Jun. 2019 ($16.90 Mil) to Sep. 2019 ($8.71 Mil).

Adynxx's annual market cap declined from Dec. 2016 ($17.50 Mil) to Dec. 2017 ($9.02 Mil) but then increased from Dec. 2017 ($9.02 Mil) to Dec. 2018 ($9.36 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Adynxx's Enterprise Value for Today is $0.00 Mil.


Adynxx Market Cap Historical Data

The historical data trend for Adynxx's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Market Cap Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.87 59.21 17.50 9.02 9.36

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.36 9.36 14.72 16.90 8.71

Competitive Comparison of Adynxx's Market Cap

For the Biotechnology subindustry, Adynxx's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Market Cap distribution charts can be found below:

* The bar in red indicates where Adynxx's Market Cap falls into.



Adynxx Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Adynxx's Market Cap for the fiscal year that ended in Dec. 2018 is calculated as

Market Cap (A: Dec. 2018 )=Share Price (A: Dec. 2018 )*Shares Outstanding (EOP) (A: Dec. 2018 )
=$11.22*0.8342
=$9.36

Adynxx's Market Cap for the quarter that ended in Sep. 2019 is calculated as

Market Cap (Q: Sep. 2019 )=Share Price (Q: Sep. 2019 )*Shares Outstanding (EOP) (Q: Sep. 2019 )
=$1.5*5.80788
=$8.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adynxx  (OTCPK:ADYX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Adynxx Market Cap Related Terms

Thank you for viewing the detailed overview of Adynxx's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (Adynxx) Business Description

Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Executives
Gregory J. Flesher director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning officer: CHIEF MEDICAL OFFICER C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102